Skip to main content
News and Products

European regulatory committee recommends the suspension of marketing authorisation for some linear GBCAs

By 16th May 2017February 1st, 2019No Comments

Several years ago the world of contrast- based MRI was concerned by the occurrence of Nephrogenic Systemic Fibrosis (NSF) — a potentially serious

scarring condition in patients with kidney impairment — associated with the administration of Gadolinium Based Contrast Agents (GBCAs) in patients

with impaired renal function. Studies into NSF prompted the categorisation of GBCAs into low-, mid- and high-risk categories depending on the chemical structure

of the molecule used to chelate the gadolinium ion itself

Read More